Frankfurt
12.08.24
15:29 Uhr
0,048 Euro
0,000
0,00 %
0,00 %
1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.08. | Biotech Destiny Pharma Tips Into Insolvency in Cash Crisis | 3 | BNN Bloomberg | ||
| 20.08. | JP Jenkins Ltd: Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula | 325 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative... ► Artikel lesen | |
| 14.08. | JP Jenkins Ltd: Destiny Pharma initiates research to explore XF drug potential for CF | 281 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma initiates research to explore XF drug potential for CF 14-Aug-2024 / 11:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| 13.08. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.08.2024 | 471 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 13.08.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.08.2024ISIN NameCA44053J4090 HORIZON... ► Artikel lesen | |
| DESTINY PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.08. | JP Jenkins Ltd: Destiny Pharma plc shares now trading on JP Jenkins | 211 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma plc shares now trading on JP Jenkins 13-Aug-2024 / 09:36 GMT/BST
The issuer is solely responsible for the content of this announcement.
13th Aug... ► Artikel lesen | |
| 13.08. | AIM - Cancellation - Destiny Pharma plc | 1 | RNS | ||
| 13.08. | XFRA D89: AUSSETZUNG/SUSPENSION | 165 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDESTINY PHARMA PLC... ► Artikel lesen | |
| 12.08. | Destiny Pharma PLC - Last Day of Dealings on AIM | - | RNS | ||
| 06.08. | FTSE Russell - Destiny Pharma: Constituent Deletion - Changes in FTSE UK Index Series | 2 | RNS | ||
| 05.08. | Small Cap Stocks: Destiny Pharma, Tower Resources, UK Oil & Gas | 2 | The Armchair Trader | ||
| 05.08. | Destiny Pharma reports positive findings from XF-73 study | 1 | Sharecast | ||
| 05.08. | Destiny Pharma PLC - Director/PDMR Shareholding | 1 | RNS | ||
| 05.08. | Destiny Pharma shares fall amid XF-73 fending off MRSA in wounds | 1 | Alliance News | ||
| 05.08. | Destiny Pharma PLC - XF-73 prevents bacterial invasion of bloodstream | 1 | RNS | ||
| 31.07. | Destiny Pharma PLC - Result of GM and Cancellation of Trading on AIM | 1 | RNS | ||
| 22.07. | Small Cap Stocks: Future Metals, Wishbone Gold, Destiny Pharma | 4 | The Armchair Trader | ||
| 22.07. | Destiny Pharma PLC - Treatment of XF-73 Nasal reduces antibiotic use | 1 | RNS | ||
| 15.07. | Small Cap Stocks: Gfinity, Caspian Sunrise, Destiny Pharma | 2 | The Armchair Trader | ||
| 15.07. | London markets weak at midday, Burberry, Destiny Pharma smashed | 4 | Shares | ||
| 15.07. | AIM WINNERS & LOSERS: Destiny Pharma falls on plans to go private | 1 | Alliance News |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
| SKINBIOTHERAPEUTICS | 0,178 | -3,26 % | SkinBioTherapeutics posts revenue growth and strategic acquisitions | ||
| DYNE THERAPEUTICS | 29,500 | 0,00 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,010 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,710 | 0,00 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| IMMUNOVANT | 28,620 | 0,00 % | Immunovant Inc.: Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 | Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 46,670 | 0,00 % | Kymera International erwirbt Coating Center Castrop GmbH | Research Triangle Park, North Carolina (ots/PRNewswire) - -- Kymera erweitert Präsenz seiner Sparte Oberflächentechnologien in Europa und erleichtert Kunden den Zugang zu fortschrittlichen Lösungen... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 69,85 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study... ► Artikel lesen | |
| BIONTECH | 116,30 | +0,87 % | Evotec, Vidac Pharma, BioNTech - Krebsforschung: Die Goldgrube im Depot | Investitionen in Aktiengesellschaften, die im Bereich der Onkologieforschung tätig sind, bieten vielversprechende Renditechancen und langfristige Stabilität. Der Onkologiemarkt gehört zu den wachstumsstärksten... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,460 | 0,00 % | PTA-News: Small- & MicroCap Investment: Die +440 %-Chance: NurExone mit dreistelligem Gewinn wie Vera Therapeutics oder Viking Therapeutics? | DJ PTA-News: Small- & MicroCap Investment: Die +440 %-Chance: NurExone mit dreistelligem Gewinn wie Vera Therapeutics oder Viking Therapeutics?
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| JANUX THERAPEUTICS | 64,75 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| EVOTEC | 8,810 | +0,46 % | UNGLAUBLICHE Sondermeldung bei Evotec Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| ARCTURUS THERAPEUTICS | 19,090 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| QIAGEN | 41,115 | -0,25 % | Biotech Report: Evotec und Qiagen behauptet; US-Sektor legt zu | (shareribs.com) Frankfurt / New York 04.12.2024 - Biotech-Aktien zeigten sich im deutschen Handel überwiegend leichter. Unter anderem gaben 4SC und Vita34 nach. Für Evotec ging es leicht nach oben.... ► Artikel lesen | |
| NEUMORA THERAPEUTICS | 10,290 | 0,00 % | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating... ► Artikel lesen |
Das Unternehmen DESTINY PHARMA PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,048 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DESTINY PHARMA PLC finden Sie auf Wallstreet Online.
